Diagnostic methods and biomarkers for alzheimer’s disease

Toxicology and Environmental Health Sciences

Volumn 6, Issue 3, 2014, Pages 133-147

  Bagyinszky, Eva ^a   Youn, Young Chul ^b   An, Seong Soo A ^a   Kim, Sangyun ^c  

^a Gachon University   (South Korea)

^b Chung Ang University College of Medicine   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Alzheimer s diseases; Amyloid beta; Biomarkers; Diagnosis

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; ANTIOXIDANT; APOLIPOPROTEIN E; BIOLOGICAL MARKER; CARBON 11; COMPLEMENT COMPONENT C1Q; FLOBETAPIR; FLUORINE 18; FLUTEMETAMOL F 18; HOMOCYSTEINE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; ISOPROSTANE DERIVATIVE; PITTSBURGH COMPOUND B; PRESENILIN 1; PRESENILIN 2; REACTIVE OXYGEN METABOLITE; RETINOL BINDING PROTEIN; TAU PROTEIN; TRACER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLELE; ALZHEIMER DISEASE; ARTICLE; BLOOD ANALYSIS; BRAIN METABOLISM; CEREBROSPINAL FLUID; DEMENTIA; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; IMMUNOASSAY; MASS SPECTROMETRY; MEDIAL TEMPORAL LOBE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEOMICS; PSYCHOANALYSIS; RAPID TEST; SALIVA ANALYSIS; TWO DIMENSIONAL ELECTROPHORESIS;

EID: 84933525945     PISSN: 20059752     EISSN: 22337784     Source Type: Journal    
DOI: 10.1007/s13530-014-0198-5     Document Type: Article

References (142)

1. Bird, D. T. Genetic Aspects of Alzheimer Disease. Genet. Med. 10, 231–239 (2008).
2. Knopman, D. S. et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56, 1143–1153 (2001).
3. Perl, D. P. Neuropathology of Alzheimer’s disease. Mt. Sinai. J. Med. 77, 32–42 (2010).
4. Zhu, C. W. & Sano, M. Economic considerations in the management of Alzheimer’s disease. Clin. Interv. Aging 1, 143–154 (2006).
5. Iversen, L. L. The toxicity in vitro of beta-amyloid protein. Biochem. J. 311, 1–16 (1995).
6. Monien, B. H., Apostolova, L. G. & Bitan, G. Early diagnostics and therapeutics for Alzheimer’s disease-how early can we get there? Expert. Rev. Neurother. 6, 1293–1306 (2006).
7. Wolk, D. A. & Klunk, W. Update on amyloid imaging: from healthy aging to Alzheimer’s disease. Curr. Neurol. Neurosci. Rep. 9, 345–352 (2009).
8. Chertkow, H. Diagnosis and treatment of dementia: Introduction. Introducing a series based on the Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia. Canadian Medical Association 178, 316–321 (2008).
9. Hebert, L. E. Scherr, P. A., Bienias, J. L., Bennett, D. A. & Evans, D. A. Alzheimer Disease in the US Population, Prevalence Estimates Using the 2000 Census. Arch Neurol. 60, 1119–1122 (2003).
10. Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimer’s and Dement. 6, 158–194 (2010).
11. Canadian study of health and aging: study methods and prevalence of dementia. CMAJ 150, 899–913 (1994).
12. Herrmann, N. & Gauthier, S. Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease. CMAJ 179, 1279–1287 (2008).
13. Suh, G. H. et al. A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer’s disease in a Korean population. J. Korean. Med. Sci. 23, 10–17 (2008).
14. Park, H. K. et al. Clinical characteristics of a nationwide hospital-based registry of mild-to-moderate Alzheimer’s disease patients in Korea: a CREDOS (Clinical Research Center for Dementia of South Korea) study. J. Korean Med. Sci. 26, 1219–1222 (2011).
15. Development of the English version of the Clinical Practice Guideline for Dementia-Part I: Diagnosis & Evaluation was partially supported by the Office of Research Planning and Management, clinical practice guideline support National Evidence-based Healthcare Collaborating Agency, Seoul, Republic of Korea (http://jkma.org/src/SM/jkma-54-861-s002.pdf).
16. Selkoe, D. J. Alzheimer’s Disease: Genes, Proteins, and Therapy. Physiol. Rev. 81, 741–766 (2001).
17. National Institute on Aging. Progress Report on Alzheimer’s Disease. Bethesda, MD: National Institute on Aging (1998).
18. Rice, D. P. et al. Prevalence, costs, and treatment of Alzheimer’s disease and related dementia: a managed care perspective. Am. J. Manag. Care 7, 809–818 (2001).
19. Zhu, C. W. et al. Longitudinal study of effects of patient characteristics on direct costs in Alzheimer disease. Neurology 67, 998–1005 (2006).
20. Hogan, D. B. et al. Diagnosis and treatment of dementia: 4. Approach to management of mild to moderate dementia. CMAJ 179, 787–793 (2008).
21. Chertkow, H. et al. Diagnosis and treatment of dementia: 3. Mild cognitive impairment and cognitive impairment without dementia. CMAJ 178, 1273–1285 (2008).
22. Gauthier, S. et al. Mild cognitive impairment. Lancet 367, 1262–1270 (2006).
23. Dubois, B. & Albert, M. L. Amnestic MCI or prodromal Alzheimer’s disease? Lancet Neurol. 3, 246–248 (2004).
24. Smith, G. Is mild cognitive impairment bridging the gap between normal aging and Alzheimer’s disease? J. Neural. Transm. Suppl. 62, 97–104 (2002).
25. Weimer, D. L. & Sager, M. A. Early identification and treatment of Alzheimer’s disease: Social and fiscal outcomes. Alzheimers Dement. 5, 215–226 (2009).
26. Valcour, V. G., Masaki, K. H., Curb, J. D. & Blanchette, P. L. The Detection of Dementia in the Primary Care Setting. Arch InterMed. 160, 2964–2968 (2000).
27. Musicco, M. et al. Predictors of progression of cognitive decline in Alzheimer’s disease: the role of vascular and sociodemographic factors. J. Neurol. 256, 1288–1295 (2009).
28. Spooner, M. A. Is it really Alzheimer’s? Can. Fam. Physician 40, 1141–1145 (1994).
29. Desikan, R. S. et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 31, 968–980 (2006).
30. Jagust, W. Mapping Brain β-Amyloid. Curr. Opin. Neurol. 22, 356–361 (2010).
31. Horn, A. H. & Sticht, H. Amyloid-beta42 oligomer structures from fibrils: a systematic molecular dynamics study. J. Phys. Chem. B. 114, 2219–2226 (2010).
32. Buchete, N. V., Tycko, R. & Humme, G. Molecular Dynamics Simulations of Alzheimer’s β-Amyloid Protofilaments. J. Mol. Biol. 353, 804–821 (2005).
33. Serpell, L. C. Alzheimer’s amyloid fibrils: structure and assembly. Biochim. Biophys. Acta. 1502, 16–30 (2000).
34. Chow, V. W., Mattson, M. P., Wong, P. C. & Gleichmann, M. An Overview of APP Processing Enzymes and Products. Neuromolecular. Med. 12, 1–12 (2009).
35. Evin, G., Sernee, M. F. & Masters, C. L. Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer’s disease: prospects, limitations and strategies. CNS Drugs 20, 351–372 (2006).
36. Vassar, R. BACE1: the beta-secretase enzyme in Alzheimer’s disease. J. Mol. Neurosci. 23, 105–114 (2004).
37. Irizarry, M. C. Biomarkers of Alzheimer Disease in Plasma. NeuroRx. 1, 226–234 (2004).
38. Blennow, K. CSF biomarkers for mild cognitive impairment. J. Int. Med. 256, 224–234 (2004).
39. Feldman, H. H. et al. Diagnosis and treatment of dementia: 2. Diagnosis. CMAJ 178, 825–836 (2008).
40. Frank, R. A. et al. Biological markers for therapeutic trials in Alzheimer’s disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer’s disease. Biological markers for therapeutic trials in Alzheimer’s disease. Neurobiol. Aging 24, 521–536 (2003).
41. Levey, A., Lah, J., Goldstein, F., Steenland, K. & Bliwise, D. Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer’s disease. Clin Ther. 28, 991–1001 (2006).
42. Jack, C. R. et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 9, 119 (2010).
43. Patterson, C. et al. Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. CMAJ 178, 548–556 (2008).
44. Schneider, L. S., Kennedy, R. E. & Cutter, G. R. Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer’s disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimers Dement. 6, 367–377 (2010).
45. The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group. 1998, Consensus report of the Working Group on: Molecular and biochemical markers of Alzheimer’s disease. Neurobiol. Aging 19, 109–116 (1998).
46. Maarouf, C. L. et al. Proteomic Analysis of Alzheimer’s Disease Cerebrospinal Fluid from Neuropathologically Diagnosed Subjects. Curr. Alzheimer Res. 6, 399–406 (2009).
47. Butterfield, D. A., Boyd-Kimball, D. & Castegna, A. Proteomics in Alzheimer’s disease: insights into potential mechanisms of neurodegeneration. J. Neurochem. 86, 1313–1327 (2003).
48. Zhang, J., Keene, C. D., Pan, C., Montine, K. S. & Montine, T. J. Proteomics of Human Neurodegenerative Diseases. J. Neuropathol. Exp. Neurol. 67, 923–932 (2008).
49. Shi, M., Caudle, W. M. & Zhang, J. Biomarker Discovery in Neurodegenerative Diseases: A Proteomic Approach. Neurobiol. Dis. 35, 157–164 (2009).
50. Zaluzec, E. J., Gage, D. A. & Watson, J. T. Matrix-Assisted Laser Desorption Ionization Mass Spectrometry: Applications in Peptide and Protein Characterization. Protein Expr. Purif. 6, 109–123 (2002).
51. Mischak, H. et al. Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments. Mass Spectrom. Rev. 28, 703–724 (2009).
52. Ries, M. L. et al. MRI characterization of brain structure and function in Mild Cognitiven Impairment: A review. J. Am. Geriatr. Soc. 56, 920–934 (2008).
53. Mueller, S. G. et al. The Alzheimer’s Disease Neuroimaging Initiative. Neuroimaging Clin. N. Am. 15, 869–877 (2008).
54. Wahlund, L. O., Julin, P., Johansson, S. E. & Scheltens, P. Visual rating and volumetry of the medial temporal lobe on magnetic resonance imaging indementia: a comparative study. J. Neurol. Neurosurg. Psychiatry 69, 630–635 (2000).
55. DeCarli, C. et al. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch. Neurol. 1, 108–115 (2007).
56. Duara, R. et al. Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer disease. Neurology 71, 1986–1992 (2008).
57. den Heijer, T. et al. A 10-year follow-up of hippocampal volume on magnetic resonancen imaging in early dementia and cognitive decline. Brain 133, 1163–1172 (2010).
58. Killiany, R. J. et al. Use of structural magnetic resonance imaging to predict who will get Alzheimer’s disease. Ann. Neurol. 47, 430–439 (2000).
59. Scahill, R. I., Schott, J. M., Stevens, J. M., Rossor, M. N. & Fox, N. C. Mapping the evolution of regional atrophy in Alzheimer’s disease: unbiased analysis of fluid-registered serial MRI. Proc. Natl. Acad. Sci. USA 99, 4703–4707 (2002).
60. Du, A. T. et al. Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry 71, 441–447 (2001).
61. Borthakur, A., Sochor, M., Davatzikos, C., Trojanowski, J. Q. & Clark, C. M. T1rho MRI of Alzheimer’s disease. Neuroimage 41, 1199–1205 (2008).
62. Haris et al. T (1ρ) MRI in Alzheimer’s disease: detection of pathological changes in medial temporal lobe.J. Neuroimaging 21, 86–90 (2011).
63. Phelps, M. E. PET: the merging of biology and imaging into molecular imaging. J. Nucl. Med. 41, 661–681 (2000).
64. Wolk, D. A. & Klunk, W. E. Update on Amyloid Imaging: From Healthy Aging to Alzheimer’s Disease. Curr. Neurol. Neurosci. Rep. 9, 345–352 (2009).
65. Klunk, W. E. et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann. Neurol. 55, 306–319 (2004).
66. Kudo, Y. et al. 2-(2-[2-Dimethylaminothiazol-5-yl] ethenyl)-6-(2-[fluoro]ethoxy) benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer’s disease patients. J. Nucl. Med. 48, 553–561 (2007).
67. Verhoeff, N. P. et al. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am. J. Geriatr. Psychiatry 12, 584–595 (2004).
68. Shoghi-Jadid, K. et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am. J. Geriatr. Psychiatry 10, 24–35 (2002).
69. Small, G. W. et al. PET of brain amyloid and tau in mild cognitive impairment. N. Engl. J. Med. 355, 2652–2663 (2006).
70. Rowe, C. C. et al. Imaging of amyloid β in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 7, 129–135 (2008).
71. Alexander, G. E., Chen, K., Pietrini, P., Rapoport, S. I. & Reiman, E. M. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer’s Disease Treatment Studies. Am. J. Psychiatry 159, 738–745 (2002).
72. Waragai, M. et al. Comparison study of amyloid PET and voxel-based morphometry analysis in mild cognitive impairment and Alzheimer’s disease. J. Neurol. Sci. 285, 100–108 (2004).
73. Bohnen, N. I., Djang, D. S., Herholz, K., Anzai, Y. & Minoshima, S. Effectiveness and Safety of 18FFDG PET in the Evaluation of Dementia: A Review of the Recent Literature. J. Nucl. Med. 53, 59–71 (2011).
74. Wong, D. F. et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18FAV-45 (florbetapir [corrected] F 18). J. Nucl. Med. 51, 913–920 (2010).
75. Nelissen, N. et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J. Nucl. Med. 50, 1251–1259 (2009).
76. Waring, S. C. & Rosenberg, R. N. Genome-wide association studies in Alzheimer disease. Arch. Neurol.65, 329–334 (2008).
77. Mann, D. et al. Preferential deposition of amyloid β protein (Aβ) in the form Aβ40 in Alzheimer’s disease is associated with a gene dosage effect of the apolipoprotein E E4 allele. Neurosci. Lett. 221, 81–84 (1997).
78. Thambisetty, M., Beason-Held, L., An, L. Y., Kraut, M. A. & Resnick, S. M. APOE epsilon4 genotype and longitudinal changes in cerebral blood flow in normal aging. Arch. Neurol. 67, 93–98 (2010).
79. Scheuner, D. et al. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat. Med. 2, 864–870 (1996).
80. Humpel, C. Editorial to biomarkers of Alzheimers disease and dementia in cerebrospinal fluid and blood.Exp. Gerontol. 45, 1 (2010).
81. Di Luca, M. et al. Abnormal Pattern of Platelet APP Isoforms in Alzheimer Disease and Down Syndrome.Arch. Neurol. 53, 1162–1166 (1996).
82. Holtzman, D. M. et al. Apolipoprotein E isoformdependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 97, 2892–2897 (2000).
83. Ye, S. et al. Apolipoprotein (apo) E4 enhances amyloid β peptide production in cultured neuronal cells: ApoE structure as a potential therapeutic target. Proc. Natl. Acad. Sci. USA 102, 18700–18705 (2005).
84. Huang, Y., Weisgraber, K. H., Mucke, L. & Mahley, R. W. Apolipoprotein E: diversity of cellular origins, structural and biophysical properties, and effects in Alzheimer’s disease. J. Mol. Neurosci. 23, 189–204 (2004).
85. Huang, Y. et al. Apolipoprotein E fragments present in Alzheimer’s disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. PNAS 98, 8838–8843 (2001).
86. Brodbeck, J. et al. Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neurons. PNAS 105, 1343–1346 (2007).
87. Buttini, M. et al. Expression of Human Apolipoprotein E3 or E4 in the Brains of Apoe-/- Mice: Isoform-Specific Effects on Neurodegeneration. J. Neurosci. 19, 4867–4880 (1999).
88. Shaftel, S. S., Griffin, W. S. & O’Banion, M. K. The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J. Neuroinflammation 5, 7 (2008).
89. Forlenza, O. V. et al. Increased serum IL-1beta level in Alzheimer’s disease and mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 28, 507–512 (2009).
90. Licastro, F. et al. Increased plasma levels of interleukin-1, interleukin-6 and α-1-antichymotrypsin in patients with Alzheimer’s disease: peripheral inflammation or signals from the brain? J. Neuroimmunol. 103, 97–102 (2000).
91. Ershler, W. B. et al. Interleukin-6 and aging: blood levels and mononuclear cell production increase with advancing age and in vitro production is modifiable by dietary restriction. Lymphokine Cytokine Res. 12, 225–230 (1993).
92. Ribizzi, G., Fiordoro, S., Barocci, S., Ferrari, E. & Megna, M. Cytokine polymorphisms and Alzheimer disease: possible associations. Neurol. Sci. 31, 321–325 (2010).
93. Praticò, D. Alzheimer’s disease and oxygen radicals: new insights. Biochem. Pharmacol. 63, 563–567 (2001).
94. Markesbery, W. R. & Carney, J. M. Oxidative alterations in Alzheimer’s disease. Brain Pathol. 9, 133–146 (1999).
95. Fusco, D., Colloca, G., Lo Monaco, M. R. and Cesari, M. Effects of antioxidant supplementation on the aging process. Clin. Interv. Aging 2, 377–387 (2007).
96. Foy, C. J., Passmore, A. P., Vahidassr, M. D., Young, I. S. & Lawson, J. T. Plasma chain-breaking antioxidants in Alzheimer’s disease, vascular dementia and Parkinson’s disease. QJM 92, 39–45 (1999).
97. Xiong, H. et al. Cholesterol retention in Alzheimer’s brain is responsible for high β- and γ-secretase activities and Aβ production. Neurobiol. Dis. 29, 422–437 (2008).
98. Wolozin, B. A fluid connection: Cholesterol and Aβ. Proc. Natl. Acad. Sci. USA 98, 5371–5373 (2001).
99. Hall, K. et al. 2006, Cholesterol, APOE genotype, and Alzheimer disease. Neurology 66, 223–227 (2006).
100. Schiele, F. et al. Apolipoprotein E serum concentration and polymorphism in six European countries: the Apo Europe Project. Atherosclerosis 152, 475–488 (2000).
101. Glushchenko, A. V. & Jacobsen, D. W. Molecular Targeting of Proteins by l-Homocysteine: Mechanistic Implications for Vascular Disease. Antioxid. Redox. Signal 9, 1883–1898 (2007).
102. Laukka, E. J., Fratiglioni, L. & Bäckman, L. The influence of vascular disease on cognitive performance in the preclinical and early phases of Alzheimer’s disease. Dement. Geriatr. Cogn. Disord. 29, 498–503 (2010).
103. Stellos, K. et al. Predictive value of platelet activation for the rate of cognitive decline in Alzheimer’s disease patients. J. Cereb. Blood Flow Metab. 30, 1–4 (2010).
104. Stellos, K., Bigalke, B., Stakos, D., Henkelmann, N. & Gawaz, M. Platelet-bound P-selectin expression in patients with coronary artery disease: impact on clinical presentation and myocardial necrosis, and effect of diabetes mellitus and anti-platelet medication. J. Thromb. Haemost. 8, 205–207 (2010).
105. Song, F., Poljak, A., Smythe, G. A. & Sachdev, P. Plasma biomarkers for mild cognitive impairment and Alzheimer’s disease, Brain Research Reviews 61, 69–80 (2009).
106. van Oijen, M., Hofman, A., Soares, H. D., Koudstaal, P. J. & Breteler, M. M. Plasma Abeta (1–40) and Abeta (1–42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 5, 655–660 (2006).
107. Solfrizzi, V. et al. 2006, Circulating biomarkers of cognitive decline and dementia. Clin. Chim. Acta 364, 91–112 (2006).
108. Brys, M. et al. Magnetic Resonance Imaging Improves Cerebrospinal Fluid Biomarkers in the Early Detection of Alzheimer’s Disease. J. Alzheimers Dis. 16, 351–362 (2009).
109. Bjerke, M. et al. Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid. Int. J. Alzheimer Dis. pii: 986310 (2010).
110. Caballero, J. & Nahata, M. Do statins slow down Alzheimer’s disease? A review. J. Clin. Pharm. Ther.29, 209–213 (2004).
111. Gabelle, A. et al. Correlations between soluble α/β forms of amyloid precursor protein and Aβ38, 40, and 42 in humancerebrospinal fluid. Brain Res. 1357, 175–183 (2010).
112. Blennow, K. Cerebrospinal Fluid Protein Biomarkers for Alzheimer’s Disease. NeuroRx. 1, 213–225 (2004).
113. Fukuyama, R. et al. Age-dependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Abeta42 to Abeta40 level in cerebrospinal fluid from Alzheimer’s disease patients. Eur. Neurol. 43, 155–160 (2000).
114. Yerbury, J. J. & Wilson, M. R. Extracellular chaperones modulate the effects of Alzheimer’s patient cerebrospinal fluid on Aβ1-42 toxicity and uptake. Cell Stress Chaperones 15, 115–121 (2009).
115. Craig-Schapiro, R., Fagan, A. M. & Holtzman, D. M. Biomarkers of Alzheimer’s Disease. Neurobiol. Dis.35, 128–140 (2009).
116. Lee, J. W. et al. Fibrinogen gamma-A chain precursor in CSF: a candidate biomarker for Alzheimer’s disease. BMC Neurol. 7, 14 (2007).
117. Jung, S. M. et al. Both plasmaretinol-binding protein and haptoglobin precursor allele 1 in CSF: Candidate biomarkers for the progression of normal to mild cognitive impairment to Alzheimer’s disease. Neurosci. Lett.436, 153–157 (2008).
118. Hu, Y. Y. et al. Elevated levels of phosphorylated neurofilament proteins incerebrospinal fluid of Alzheimer disease patients. Neurosci. Lett. 320, 156–160 (2002).
119. Blennow, K., Davidsson, P., Wallin, A., Gottfries, C. G. & Svennerholm, L. Ubiquitin in cerebrospinal fluid in Alzheimer’s disease and vascular dementia. Int. Psychogeriatr. 6, 13–22 (1994).
120. Praticò, D. et al. Increased 8, 12-iso-iPF (2α) -VI in Alzheimer’s disease: Correlation of a noninvasive index of lipid peroxidation with disease severity. Ann. Neurol. 48, 809–812 (2000).
121. Skovronsky, D. M., Lee, V. M. Y. & Praticò, D. Amyloid Precursor Protein and Amyloid β Peptide in Human Platelets. J. Biol. Chem. 276, 17036–17043 (2001).
122. Anoop, A., Singh, P. K., Jacob, R. S. & Maji, S. K. CSF Biomarkers for Alzheimer’s Disease Diagnosis. Int. J. Alzheimers Dis. pii: 606802 (2010).
123. Stefani, A. et al. CSF biomarkers, impairment of cerebral hemodynamics and degree of cognitive decline in Alzheimer’s and mixed dementia. J. Neurol. Sci. 283, 109–115 (2009).
124. Fagan, A. M. et al. Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer’s disease. EMBO Mol. Med. 1, 371–380 (2009).
125. Bian, H. et al. CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology 70, 1827–1835 (2008).
126. Sunderland, T. et al. Cerebrospinal fluid β-amyloid1-42 and tau in control subjects at risk for Alzheimer’s disease: The effect of APOE ε4 allele. Biol. Psychiatry 56, 670–676 (2004).
127. Azad, N. S. et al. Proteomics in Clinical Trials and Practice. Proteomics 5, 1819–1829 (2006).
128. Fukumoto, H. et al. High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J. 24, 2716–2726 (2010).
129. Picone, P. et al. Abeta oligomers and fibrillar aggregates induce different apoptotic pathways in LAN5 neuroblastoma cell cultures. Biophys. J. 96, 4200–4211 (2009).
130. Homepage of American Alzheimer’s Disease Neuroimaging Initiative (ADNI) http://www.adni-info.org/index.
131. Petersen, R. C. Prediction and Prevention (?) of Alzheimer’s Disease. Lancet Neurol. 9, 4–5 (2010).
132. Cheng, I. H. et al. Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J. Biol. Chem. 282, 23818–23128 (2007).
133. Lesné, S., Kotilinek, L. & Ashe, K. H. Plaque-bearing mice with reduced levels of oligomeric amyloid-beta assemblies have intact memory function. Neuroscience 151, 745–749 (2007).
134. Hashimoto, T., Adams, K. W., Fan, Z., McLean, P. J. & Hyman, B. T. Characterization of oligomer formation of amyloid-beta peptide using a split-luciferase complementation assay. J. Biol. Chem. 286, 27081–27091 (2011).
135. Olsson, A. et al. Simultaneous measurement of betaamyloid (1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin. Chem. 51, 336–345 (2005).
136. Bao, F. et al. Different β-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity. Neurobiol. Aging 33, 825.e1-1 (2011).
137. Hu, Y. et al. A strategy for designing a peptide probe for detection of β-amyloid oligomers. Chembiochem 11, 2409–2418 (2010).
138. Ojha, J., Masilamoni, G., Dunlap, D., Udoff, R. A. & Cashikar, A. G. Sequestration of toxic oligomers by HspB1 as a cytoprotective mechanism. Mol. Cell Biol. 31, 3146–3157 (2011).
139. Sayer, R., Law, E., Connelly, P. J. & Breen, K. C. Association of a salivary acetylcholinesterase with Alzheimer’s disease and response to cholinesterase inhibitors. Clin. Biochem. 37, 98–104 (2004).
140. Bermejo-Pareja, F., Antequera, D., Vargas, T., Molina, J. A. & Carro, E. Saliva levels of Abeta1-42 as potential biomarker of Alzheimer’s disease: a pilot study. BMC Neurol. 10, 108 (2010).
141. Homepage of Oasis Diagnostic: http://www.4saliva.com.
142. Perrin, R. J., Fagan, A. M. & Holtzman, D. M. Multimodal techniques for diagnosis and prognosis of Alzheimer’s disease. Nature 461, 916–922 (2009)